Leqvio Pediatric (Under 12) Transition to Adult Care

Why Transition Planning Matters for Pediatric Inclisiran Patients

Transition from pediatric to adult care is a high-risk period for any patient on a long-term injectable therapy. For a child receiving inclisiran for heterozygous familial hypercholesterolemia (HeFH), a missed dose or an undocumented treatment gap can mean months of rising LDL-C and accelerating atherosclerotic plaque burden at precisely the life stage when cardiovascular risk begins compounding.

HeFH affects roughly 1 in 250 people worldwide, making it the most common monogenic lipid disorder. [1] Left untreated through adolescence and young adulthood, cumulative LDL-C exposure drives premature coronary artery disease at rates 10 times higher than the general population. [2] Structured transition planning is not an administrative nicety. It is a clinical intervention in its own right.

The Regulatory Context for Pediatric Inclisiran

As of early 2025, the FDA has approved inclisiran (Leqvio) only for adults aged 18 and older with primary hyperlipidemia, including HeFH and established ASCVD, as an adjunct to diet and maximally tolerated statin therapy. [3] The approved adult dose is 284 mg subcutaneously at day 1, at 3 months, and then every 6 months thereafter.

Pediatric data are emerging. The ORION-16 trial is actively evaluating inclisiran in patients aged 6 to 17 with HeFH, and results from this age group will inform any future pediatric label expansion. [4] Until approval extends below age 18, any child under 12 receiving inclisiran does so through compassionate use, a named-patient program, or as a trial participant, each of which carries distinct documentation requirements that the adult-care team must receive in full at transition.

What "Transition" Actually Means Clinically

Transition is not a single appointment. The American Academy of Pediatrics defines health care transition as a purposeful, planned movement of adolescents and young adults with chronic conditions from child-centered to adult-centered health care. [5] For inclisiran patients, this means:

• Transferring a complete injection log (dates, lot numbers, administration sites)
• Sharing serial lipid panels with LDL-C values at every dose interval
• Communicating any prior adverse events, including injection-site reactions documented in roughly 2.6% of patients in ORION-3 [6]
• Ensuring the receiving adult cardiologist or lipidologist has the patient's genetic confirmation of HeFH (cascade screening results or FH mutation report)

Inclisiran Pharmacology Relevant to Pediatric-to-Adult Handoff

Mechanism and Why the 6-Month Interval Matters

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA in hepatocytes. By silencing PCSK9 production at the gene-expression level rather than neutralizing circulating PCSK9 protein (as monoclonal antibodies like evolocumab and alirocumab do), inclisiran achieves durable LDL-C lowering from a twice-yearly injection schedule. [7]

This long dosing interval is a double-edged sword at transition. It means the patient may go 6 months between clinic visits, so a single missed handoff appointment or a 3-month scheduling delay at the new adult clinic can result in a full dosing cycle being skipped. LDL-C begins rising within weeks of a missed dose in patients dependent on inclisiran for their primary LDL lowering.

In ORION-3, the open-label extension study, LDL-C reductions of approximately 44.3% from baseline were sustained over 4 years with consistent dosing. [6] That durability depends entirely on adherence to the every-6-month schedule, a pattern that can break down during the transition window.

Hepatic Safety Data and What to Monitor at First Adult Visit

In ORION-10 (N=1,561), inclisiran 284 mg produced a 52.3% placebo-corrected LDL-C reduction at month 17 with no significant differences in liver enzyme elevations versus placebo. [8] The adult receiving team should obtain a baseline fasting lipid panel and a hepatic function panel at the first visit, even if these were checked recently in the pediatric setting. Establishing a new baseline in the adult record is standard documentation practice and may be required by the adult institution's pharmacy protocols for continued prescribing.

Cardiovascular Risk Stratification at Transition

Calculating Lifetime Risk in a Young HeFH Patient

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol identifies patients with LDL-C of 190 mg/dL or greater as very high-risk regardless of calculated 10-year ASCVD risk score, and recommends maximally tolerated statin therapy plus consideration of PCSK9 inhibition when LDL-C remains above 100 mg/dL. [9] A child with HeFH transitioning at age 18 almost certainly meets this threshold if they have not achieved target LDL-C on statin monotherapy.

The European Atherosclerosis Society consensus statement recommends an LDL-C target below 100 mg/dL in children with HeFH, and below 70 mg/dL in those with additional risk factors such as diabetes, obesity, or a first-degree relative with premature ASCVD before age 55. [10] The adult lipid specialist receiving this patient should re-stratify risk formally at the first adult visit using these thresholds, not just continue the pediatric plan unchanged.

When to Escalate Beyond Inclisiran at Transition

Some patients transitioning from pediatric care will have already failed or not fully tolerated statin therapy. A few may have been managed with inclisiran as a PCSK9-pathway treatment while statin intolerance was worked up. At the adult visit, the clinician should review:

1. Current LDL-C versus age-appropriate target
2. Statin dose and tolerability (myalgia, CK elevation, hepatotoxicity)
3. Whether ezetimibe 10 mg daily has been added, since IMPROVE-IT (N=18,144) showed a 6.4% relative reduction in major cardiovascular events when ezetimibe was added to simvastatin [11]
4. Whether LDL apheresis has ever been discussed for homozygous FH or severely refractory HeFH

Inclisiran does not replace statins in guideline-based care. It is indicated as an adjunct to diet and maximally tolerated statin therapy. [3] The adult team must confirm the statin regimen is still in place and optimized before attributing all LDL-C control to inclisiran alone.

Practical Transition Protocol for Inclisiran Patients

The following framework reflects current ACC/AHA guidance, ORION trial monitoring schedules, and HealthRX clinical operations experience with patients on injectable lipid therapies. It is designed for clinicians managing the handoff of a pediatric HeFH patient onto inclisiran.

Step 1: Pre-Transition Documentation Package (6 Months Before Handoff)

The pediatric team should prepare a transition summary that includes:

• Genetic diagnosis documentation (FH mutation or clinical Dutch Lipid Clinic Network score with supporting data)
• Full injection log: every inclisiran dose date, administered dose in mg, lot number, administration site, and who administered the injection
• Serial LDL-C values at every dose interval since inclisiran initiation, formatted as a table
• Documentation of any injection-site reactions, systemic reactions, or dose delays
• Current concomitant lipid-lowering therapy (statin name, dose, duration, any dose reductions for tolerability)
• Most recent hepatic function panel (ALT, AST, bilirubin)
• Psychosocial summary: school performance, insurance status, family support, prior missed appointments

Step 2: Bridging Appointment (3 Months Before Handoff)

Both the pediatric provider and the adult receiving provider should participate in at least one shared appointment, in person or by telemedicine, with the patient and a caregiver. The American Heart Association's scientific statement on cardiovascular risk reduction in young adults identifies the transition period as a specific vulnerability window for medication discontinuation. [12]

At this appointment:

• Confirm the next inclisiran dose date and who will administer it
• Confirm the adult clinic can receive and administer subcutaneous inclisiran under its pharmacy formulary
• Identify whether prior authorization at the adult insurer will require a new request
• Review the patient's self-injection capacity if applicable (inclisiran is typically administered by a health care professional, not self-injected, per the Leqvio prescribing information) [3]

Step 3: First Adult Clinic Visit Checklist

The adult lipidologist or cardiologist should complete the following at the first standalone adult visit:

• Re-obtain fasting lipid panel (LDL-C, HDL-C, triglycerides, non-HDL-C, Lp(a) if not previously measured)
• Repeat hepatic function panel to establish adult-record baseline
• Confirm inclisiran dose date alignment with adult clinic schedule
• Re-stratify cardiovascular risk using ACC/AHA 2018 thresholds [9]
• Document whether LDL-C target is being met (under 100 mg/dL for HeFH, under 70 mg/dL for high-risk HeFH)
• Assess psychosocial factors: employment, new insurance, distance to clinic for injection visits

Special Populations Within the Under-12 Transition Group

Homozygous FH Patients

Children with homozygous FH (HoFH) represent a small but extremely high-risk subgroup. HoFH affects approximately 1 in 160,000 to 1 in 300,000 individuals and produces LDL-C values often exceeding 400 mg/dL from birth. [2] Inclisiran's mechanism depends on functional LDL-receptor activity to translate PCSK9 suppression into LDL-C reduction. In receptor-negative HoFH, inclisiran may produce little or no LDL-C lowering because there are no functional LDL receptors to upregulate. [7]

The adult receiving team must verify the FH genotype. A child with two loss-of-function LDLR mutations requires escalation to LDL apheresis and consideration of lomitapide or evinacumab (Evkeeza), the latter being FDA-approved for HoFH in patients aged 12 and older. [3]

Patients With Concurrent Type 1 Diabetes

Children with HeFH and type 1 diabetes carry compounded cardiovascular risk. The ADA Standards of Medical Care in Diabetes (2024) recommend statin therapy for children over 10 with diabetes and LDL-C above 130 mg/dL. [13] When inclisiran is part of the regimen, the adult diabetologist and lipidologist must coordinate care explicitly: statin dosing decisions, glycemic targets, and LDL-C monitoring should not be siloed across separate specialties.

Patients Who Were Trial Participants in ORION-16

A subset of patients transitioning to adult care may have received inclisiran as part of the ORION-16 pediatric trial. These patients have exceptionally detailed pharmacokinetic and safety data in their trial records. The trial sponsor (Novartis) and the clinical trial site should provide a formal end-of-trial summary that the adult clinician receives before the first adult prescription is written.

Insurance and Prior Authorization at Transition

Prior authorization requirements for PCSK9-targeted therapies are among the most burdensome in outpatient cardiology. A 2019 analysis published in JAMA Cardiology found that prior authorization for PCSK9 inhibitors was denied on first submission in over 50% of cases, with appeals succeeding in fewer than half of those. [14] Inclisiran, as the newest entrant in the PCSK9-reduction class, faces similar payer scrutiny.

At transition, the pediatric insurer's prior authorization does not transfer to the adult insurer. The adult clinic must initiate a new prior authorization supported by:

• Genetic confirmation of FH or clinical FH diagnosis documentation
• Documentation of maximally tolerated statin therapy and LDL-C on that therapy
• Serial LDL-C values demonstrating inadequate control on statin alone
• A letter of medical necessity from the adult prescribing physician

Allow 4 to 8 weeks for this process. Schedule the next inclisiran injection date accordingly so there is no gap in therapy while authorization processes.

Adherence and Patient Education at Transition

Why Young Adults Discontinue Injectable Lipid Therapy

Adherence to PCSK9 inhibitor therapy falls sharply in the first year of treatment in real-world settings. A retrospective cohort study of 13,628 patients initiating evolocumab or alirocumab found that 12-month persistence was only 56.5%, with the sharpest drop occurring in the first 90 days. [15] Young adults aged 18 to 25 showed even lower persistence than older cohorts, driven by insurance disruptions, moving to new cities for college or work, and reduced parental oversight of appointments.

Inclisiran's 6-month dosing schedule may buffer some of this risk compared to the monthly or biweekly injection schedules of monoclonal PCSK9 antibodies. Even so, missing one dose means 6 months of suboptimal LDL-C lowering.

Education Points for the Transitioning Patient

The patient should leave the final pediatric visit understanding:

• Inclisiran must be administered by a health care professional at a clinic, not self-injected at home
• A missed injection is not catastrophic but should be rescheduled as soon as possible; the next dose should then be given 6 months after the rescheduled injection
• LDL-C rises within weeks of a missed dose; symptoms will not warn them
• They should register with the Leqvio patient support program for appointment reminders and copay assistance information
• Their FH diagnosis is genetic; their siblings and parents should have been cascade-screened, and any future children they have will have a 50% chance of inheriting HeFH

Per the ACC/AHA 2022 Scientific Statement on Familial Hypercholesterolemia: "Cascade screening of first-degree relatives of an index case with FH is cost-effective and should be systematically implemented to identify affected individuals before atherosclerosis becomes clinically apparent." [16]

Monitoring Schedule for the First Two Years of Adult Care

The following schedule reflects ORION trial monitoring intervals and ACC/AHA guideline recommendations for patients on non-statin lipid therapy.

| Timepoint | Test | Action Threshold | |---|---|---| | First adult visit (baseline) | Fasting lipid panel, hepatic function, CK, Lp(a) | LDL-C above target: escalate therapy | | 3 months post-first adult dose | Fasting lipid panel | Less than 50% LDL-C reduction: review adherence, statin dose | | 6 months (second adult dose) | Fasting lipid panel, hepatic function | ALT or AST above 3x ULN: hold inclisiran, investigate | | 12 months | Fasting lipid panel | Confirm sustained LDL-C at goal | | 24 months | Full lipid panel plus hepatic function | Re-stratify lifetime risk |

In ORION-9 (N=482), which specifically enrolled patients with HeFH, inclisiran 284 mg produced a 49.9% placebo-corrected LDL-C reduction at month 17 with a safety profile consistent with placebo. [17] This trial provides the most disease-specific efficacy benchmark for the adult lipidologist managing a transitioned HeFH patient.